REG - Morgan Stanley Cap - Rule 38.5 - ABBVIE INC.

Morgan StanleyAnnouncement

24/03/2020 11:20

RNS Number : 3640H
  
Morgan Stanley Capital Services LLC
  
24 March 2020
  
 

 
 FORM 38.5 
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)
 
DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS
 
1.             KEY INFORMATION



 Name of exempt market-maker


   Morgan Stanley Capital Services LLC




 Company dealt in


   ABBVIE INC.




 Class of relevant security to which the dealings being disclosed relate (Note 1)


  US$0.01 COMMON STOCK




 Date of dealing


   23 MARCH 2020



 
 
2.             DEALINGS (Note 2)
 
(a)           Purchases and sales



 Total number of relevant secuities accquired


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  72,056


 67.4800 USD


 62.9200 USD



 



 Total number of relevant secuities disposed


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  79,059


 67.1900 USD


 63.4150 USD



 
 
(b)           Derivatives transactions (other than options transactions)
 



 Product name, e.g. CFD


 Nature of transaction 
                (Note 4)


 Number of relevant securities 
                (Note 5)


 Price per unit




 CFD


 LONG


 100


 63.4150 USD




 CFD


 LONG


 642


 64.5000 USD




 CFD


 LONG


 450


 64.5000 USD




 CFD


 LONG


 126


 64.5000 USD




 CFD


 LONG


 77


 64.5000 USD




 CFD


 LONG


 778


 64.5000 USD




 CFD


 LONG


 1,275


 64.5000 USD




 CFD


 LONG


 90


 64.5050 USD




 CFD


 LONG


 150


 65.0933 USD




 CFD


 LONG


 120


 65.5100 USD




 CFD


 LONG


 292


 65.8045 USD




 CFD


 SHORT


 100


 62.9259 USD




 CFD


 SHORT


 600


 63.5533 USD




 CFD


 SHORT


 407


 63.7467 USD




 CFD


 SHORT


 1,212


 64.1022 USD




 CFD


 SHORT


 30,000


 64.1260 USD




 CFD


 SHORT


 328


 64.1421 USD




 CFD


 SHORT


 483


 64.1421 USD




 CFD


 SHORT


 693


 64.2441 USD




 CFD


 SHORT


 6,144


 64.4005 USD




 CFD


 SHORT


 2


 64.5000 USD




 CFD


 SHORT


 1,275


 64.5000 USD




 CFD


 SHORT


 778


 64.5000 USD




 CFD


 SHORT


 77


 64.5000 USD




 CFD


 SHORT


 2,394


 65.1313 USD




 CFD


 SHORT


 11,462


 65.1313 USD




 CFD


 SHORT


 483


 65.3941 USD




 CFD


 SHORT


 1,541


 65.3941 USD




 CFD


 SHORT


 7,794


 65.5305 USD




 CFD


 SHORT


 6,167


 66.1457 USD



 
 
(c)            Options transactions in respect of existing relevant securities
 
i)           Writing, selling, purchasing or varying
 



 Product name, eg call option


 Writing, selling, purchasing, varying etc


 Number of securities to which the option relates (Note 5)


 Exercise Price


 Type, e.g American, European etc 


 Expiry Date 


 Option money paid/received per unit (Note 3)




 N/A


 N/A


 N/A


 N/A


 N/A


 N/A


 N/A 



 
(ii) Exercising
 



 Product name, eg call option


 Number of securities


 Exercise price per unit (Note 3)




 N/A


 N/A


 N/A  



 
 
3. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 



Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 




 
 
 
 
 



 
 



 Date of disclosure


 24 MARCH 2020




 Contact Name


Craig Horsley




 Telephone Number


+44(141) 245 7736 




 Name of offeree/offeror with which connected


ABBVIE INC. 




Nature of connection (Note 6)


Advisory 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEUSARRRWUOUAR